サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1641794

ワクチンアジュバントの世界市場：タイプ別、疾患別、用途別 - 機会分析と産業予測、2024年～2035年

Vaccine Adjuvants Market By Type (Immunostimulants, Vehicles and Mucosal Adjuvants), By Disease (Infectious Diseases, Others), By Application (Research, Commercial): Global Opportunity Analysis and Industry Forecast, 2024-2035

出版日
ページ情報
英文 339 Pages
納期
2～3営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.91円
ワクチンアジュバントの世界市場：タイプ別、疾患別、用途別 - 機会分析と産業予測、2024年～2035年
出版日: 2024年12月01日
発行: Allied Market Research
ページ情報: 英文 339 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

ワクチンアジュバント市場は、2023年には8億2,020万米ドルとなり、2024年から2035年までのCAGRは3.9%を示し、2035年までには13億483万米ドルに達すると予測されています。

ワクチンアジュバントは、標的抗原に対する身体の免疫反応を強化するためにワクチンに添加される物質であり、これにより免疫の強化、迅速化、長期化が可能になります。機能的には、アジュバントは免疫細胞を刺激したり、特定の免疫経路を活性化したりすることで、免疫系が防御反応を開始するよう促す感染シグナルを模倣して機能します。この反応によりワクチンの有効性を向上させ、必要な抗原量や投与回数を減らすことができます。ビヒクルアジュバントは安定性を高め、抗原を輸送し、免疫系の認識と反応を促進します。

Vaccine Adjuvants Market-IMG1

アジュバントには、高齢者や免疫不全の人の免疫力を高め、複数の病原体に対する幅広い防御を可能にするといった利点があります。アジュバントタイプには、その安全性と有効性から広く使用されているアルミニウム塩（ミョウバン）、抗原の取り込みを促進するMF59やAS03のような水中油型エマルジョン、標的送達や放出制御を提供するリポソーム、サポニン、ナノ粒子ベースのアジュバントのような新しいタイプがあります。アジュバントタイプは、標的とする疾患に特異的な免疫反応を増強する能力に基づいて選択されるため、効果的かつ効率的なワクチンの開発において重要な役割を果たします。

ワクチンアジュバント市場は、特に新興感染症や慢性疾患において、より効果的なワクチンに対する需要の高まりによって牽引されています。インフルエンザ、肝炎、COVID-19、各種細菌感染症などの感染症発生率の増加は、幅広い防御を提供する革新的なワクチンソリューションの必要性を強調し、ワクチン需要を牽引しています。例えば、世界保健機関（WHO）が2023年に発表した論文によると、西太平洋地域では1億1,600万人がB型肝炎に、1,000万人がC型肝炎に罹患しています。この罹患率は、特に高リスク集団における免疫反応をサポートする効果的なワクチンとアジュバントの継続的な必要性を浮き彫りにし、ワクチンアジュバント市場の成長を促進しています。

ワクチンアジュバントは抗原に対する免疫反応を増強し、ワクチンの効果を高め、必要な接種回数を減らす可能性があるため、ヘルスケアへのアクセスが限られている地域では特に有益です。さらに、ワクチン開発を支援する政府の資金援助やイニシアチブも、ワクチンアジュバント市場の成長に重要な役割を果たしています。世界保健機関（WHO）などの機関や各国政府は、世界の予防接種率を向上させるため、ワクチンの研究や生産に投資しています。例えば、2023年8月、米国保健福祉省はProject NextGenを通じて14億米ドル以上の資金提供を発表しました。これには、ワクチン臨床試験への10億米ドル、新しいモノクローナル抗体治療への3億2,600万米ドル、新規ワクチン技術の研究への1億米ドルが含まれ、COVID-19ワクチン開発と治療法の進展を目指しています。

さらに、製薬企業と研究機関の協力関係の高まりは、有効性と安全性を高めた新しいアジュバントの開発につながっています。例えば、2023年10月、SPI Pharma, Inc.,（SPI）とQ-Vant Biosciences, Inc.は、Q-Vantのユニークで持続可能なサポニン抽出技術におけるリーダーシップを、SPIの世界の製薬業界へのサービス展開と専門知識に活用することで提携しました。高純度サポニンの商業規模GMP製造を拡大するための投資コミットメントと独占的商業契約により、世界の製薬企業は持続可能でスケーラブル、かつ完全に統合されたサポニンアジュバントの供給を受けることができるようになります。このようなパートナーシップは研究開発を加速させ、ワクチンアジュバント市場の成長を促進しています。

しかし、研究開発および生産に関連する高コストが市場の成長を抑制すると予想されます。アジュバント開発には、安全性と有効性を確保するための特殊技術や厳格な試験への多額の投資が必要であり、これが製造コストを上昇させます。多くの企業にとって、こうした初期コストの高さが参入障壁となり、市場参入企業が限定され、競合情勢が低下しています。さらに、特に承認基準が厳しい地域では、ワクチンアジュバントに対する規制要件が厳しく、市場の成長をさらに制限しています。

しかし、新興国におけるワクチン接種プログラムの増加や、個別化ワクチンや治療用ワクチンへの注目が、市場の成長機会をさらに高めています。これは、より多くの製薬企業やバイオテクノロジー企業が、多様化し成長するヘルスケアニーズに対応するため、新しいアジュバント技術に投資しているためです。さらに、ワクチン開発の進歩や新興国における高い成長ポテンシャルが、市場成長の機会を提供しています。

ワクチンアジュバント市場は、タイプ、疾患、用途、地域に区分されます。タイプ別では、市場は免疫刺激剤とビヒクル・粘膜アジュバントに二分されます。免疫賦活剤セグメントはさらにToll-like receptor（TLR）とその他に分類されます。疾患別では、市場は感染症とその他に分類されます。感染症セグメントはさらに肝炎とその他に分類されます。用途別では、市場は研究用と商業用に二分されます。地域別では、北米（米国、カナダ、メキシコ）、欧州（ドイツ、フランス、英国、イタリア、スペイン、その他欧州地域）、アジア太平洋（日本、中国、インド、オーストラリア、韓国、その他アジア太平洋）、中南米（ブラジル、コロンビア、アルゼンチン、その他中南米）、中東・アメリカ（GCC、アルゼンチン、その他ラテンアメリカ地域）で分析されます。

利害関係者にとっての主なメリット

  • 当レポートは、2023年から2035年までのワクチンアジュバント市場分析の市場セグメント、現在の動向、推定、力学の定量的分析を提供し、ワクチンアジュバント市場の有力な市場機会を特定します。
  • 市場促進要因、市場抑制要因、市場機会に関連する情報とともに市場調査を提供します。
  • ポーターのファイブフォース分析では、利害関係者が利益重視のビジネス決定を下し、サプライヤーとバイヤーのネットワークを強化できるように、バイヤーとサプライヤーの潜在力を強調します。
  • ワクチンアジュバント市場のセグメンテーションの詳細な分析は、市場機会を決定するのに役立ちます。
  • 各地域の主要国は、世界市場への収益貢献度に応じてマッピングされています。
  • 市場企業のポジショニングはベンチマーキングを容易にし、市場企業の現在のポジションを明確に理解することができます。
  • 本レポートには、地域および世界のワクチンアジュバント市場動向、主要企業、市場セグメント、応用分野、市場成長戦略の分析が含まれています。

本レポートで可能なレポートカスタマイズ（追加費用とスケジュールがあります。）

  • 国、地域、世界レベルでの患者/疫学データ
  • 規制ガイドライン
  • クライアントの関心に応じた追加企業プロファイル
  • 国別または地域別の追加分析-市場規模と予測
  • 企業プロファイルの拡張リスト
  • 過去の市場データ
  • SWOT分析

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

  • 市場の定義と範囲
  • 主要な調査結果
    • 主要な影響要因
    • 主要な投資機会
  • ポーターのファイブフォース分析
  • 市場力学
    • 促進要因
      • 感染症の流行増加
      • ワクチンと感染症への資金援助の拡大
      • ワクチン接種プログラムの拡大
    • 抑制要因
      • 高い初期費用と研究開発費
    • 機会
      • 新興市場における成長機会
      • ワクチンアジュバント研究の進展

第4章 ワクチンアジュバント市場：タイプ別

  • 概要
  • 免疫賦活剤
    • 免疫賦活剤ワクチンアジュバント市場：タイプ別
  • ビヒクル・粘膜アジュバント

第5章 ワクチンアジュバント市場：疾患別

  • 概要
  • 感染症
    • 感染症ワクチンアジュバント市場：タイプ別
  • その他

第6章 ワクチンアジュバント市場：用途別

  • 概要
  • 研究
  • 商業

第7章 ワクチンアジュバント市場：地域別

  • 概要
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • その他
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • オーストラリア
    • 韓国
    • その他
  • ラテンアメリカ
    • ブラジル
    • コロンビア
    • アルゼンチン
    • その他ラテンアメリカ
  • 中東・アフリカ
    • Gcc
    • 南アフリカ
    • 北アフリカ
    • その他中東・アフリカ

第8章 競争情勢

  • イントロダクション
  • 主要成功戦略
  • 主要10社の製品マッピング
  • 競合ダッシュボード
  • 競合ヒートマップ
  • 主要企業のポジショニング、2023年

第9章 企業プロファイル

  • Dynavax Technologies Corporation
  • Novovax Inc.
  • Agenus Inc.
  • Adjuvatis
  • Aurorium
  • InvivoGen
  • Croda International Plc
  • Air Liquide Group
  • Associated British Foods
  • GlaxoSmithKline plc.
目次
Product Code: A01341

The vaccine adjuvants market was valued at $820.2 million in 2023 and is estimated to reach $1,304.83 million by 2035, exhibiting a CAGR of 3.9% from 2024 to 2035.

Vaccine adjuvants are substances added to vaccines to enhance the body's immune response to the target antigen, allowing for a stronger, faster, or more prolonged immunity. Functionally, adjuvants work by stimulating immune cells or activating specific immune pathways, by mimicking infection signals that prompt the immune system to initiate a protective response. This response can improve the efficacy of vaccines, reducing the amount of antigen needed or the number of doses required. Vehicular adjuvants enhance stability, transport the antigen, and facilitate the immune system's recognition and response.

Vaccine Adjuvants Market - IMG1

Adjuvants offer advantages such as boosting immunity in older or immunocompromised individuals and enabling broad protection against multiple pathogens. Types of adjuvants include aluminum salts (alum), which are widely used for their safety and efficacy; oil-in-water emulsions like MF59 and AS03, which enhance antigen uptake; and novel types such as liposomes, saponins, and nanoparticle-based adjuvants that offer targeted delivery and controlled release. The adjuvant types are selected based on their ability to enhance immune responses specific to the disease being targeted, thus playing a crucial role in developing effective and efficient vaccines.

The vaccine adjuvants market is driven by rise in demand for more effective vaccines, especially in emerging infectious diseases and chronic conditions. Rise in incidence of infectious diseases, including flu, hepatitis, COVID-19, and various bacterial infections, emphasize the need for innovative vaccine solutions that rovide broad protection,thereby driving the demand for vaccines. For instance, according to an article published by World Health Organization (WHO) in 2023, 116 million people were living with hepatitis B and 10 million with hepatitis C in the Western Pacific Region. This incidence highlights the ongoing need for effective vaccines and adjuvants to support immune responses, particularly in high-risk populations, thereby driving the vaccine adjuvants market growth.

Vaccine adjuvants enhance the immune response to antigens, making vaccines more effective and potentially reducing the number of doses required, which is particularly beneficial in regions with limited healthcare access. In addition, the government funding and initiatives supporting vaccine development also play a significant role in the growth of the vaccine adjuvants market. Agencies such as the World Health Organization (WHO) and governments globally are investing in vaccine research and production to improve global immunization rates. For instance, in August 2023, the U.S. Department of Health and Human Services announced over $1.4 billion in funding through Project NextGen. This includes $1 billion for vaccine clinical trials, $326 million for new monoclonal antibody treatments, and $100 million to explore novel vaccine technologies, aimed at advancing COVID-19 vaccine development and therapeutics.

In addition, rise in collaborations between pharmaceutical companies and research institutions is leading to the development of new adjuvants with enhanced efficacy and safety. For instance, in October 2023, SPI Pharma, Inc., (SPI) and Q-Vant Biosciences, Inc. partnered to leverage Q-Vant's leadership in unique, sustainable saponin extraction technology with SPI's global pharmaceutical reach and expertise in servicing the industry. The investment commitment to expand commercial-scale GMP manufacturing of high-purity saponins, along with the exclusive commercial agreement, will enable global pharma customers to access a sustainable, scalable, and fully integrated supply of saponin adjuvants. These partnerships are accelerating research and development, thus propelling the growth of the vaccine adjuvants market.

However, high costs associated with research, development, and production are expected to restrain the market growth. Adjuvant development requires significant investment in specialized technologies and stringent testing to ensure safety and efficacy, which increases manufacturing costs. For many companies, these high initial costs pose a barrier to entry, limiting the number of players in the market and reducing the competitive landscape. In addition, stringent regulatory requirements for vaccine adjuvants, particularly in regions with rigorous approval standards, further restrict the market growth.

However, rise in vaccination programs in emerging countries, along with a focus on personalized and therapeutic vaccines, further enhance growth opportunities for the market, as more pharmaceutical and biotech companies invest in new adjuvant technologies to meet diverse and growing healthcare needs globally. In addition, rise in advancements in vaccine development and high growth potential in emerging countries provide an opportunity for the market growth.

The vaccine adjuvants market is segmented into type, disease, application, and region. By type, the market is bifurcated into immunostimulants and vehicles & mucosal adjuvants. The immunostimulants segment is further classified into toll-like receptor (TLR) and others. By disease, the market is segregated into infectious diseases and others. The infectious diseases segment is further classified into hepatitis and others. By application, the market is bifurcated into research and commercial. Region-wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India,Australia, South Korea, and rest of Asia-Pacific), and Latin America (Brazil, Colombia, Argentina, and Rest of LA), and Middle East Africa (GCC, South Africa, North Africa, and Rest of MEA).

Major key players that operate in the global vaccine adjuvants market are Dynavax Technologies Corporation , Novovax, Agenus Inc., Adjuvatis, Air Liquide Group, Aurorium, InvivoGen, Associated British Foods, GlaxoSmithKline plc., and Croda International Plc. Key players operating in the market have adopted agreement, acquisition, partnership, clinical trials, and product approval as their key strategies to expand their product portfolio. For instance, in May 2024, Novavax, Inc. entered into a co-exclusive licensing agreement with Sanofi. The terms of the agreement include a co-exclusive license to co-commercialize Novavax's current stand-alone adjuvanted COVID-19 vaccine worldwide.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the vaccine adjuvants market analysis from 2023 to 2035 to identify the prevailing vaccine adjuvants market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the vaccine adjuvants market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global vaccine adjuvants market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Patient/epidemiology data at country, region, global level
  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • SWOT Analysis

Key Market Segments

By Type

  • Immunostimulants
    • Type
    • Toll like receptor
    • Others
  • Vehicles and Mucosal Adjuvants

By Disease

  • Infectious Diseases
    • Type
    • Hepatitis
    • Others
  • Others

By Application

  • Research
  • Commercial

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Colombia
    • Argentina
    • Rest of Latin America
  • Middle East and Africa
    • Gcc
    • South Africa
    • North Africa
    • Rest of Middle East And Africa

Key Market Players:

    • Agenus Inc.
    • Novovax Inc.
    • Aurorium
    • Air Liquide Group
    • Adjuvatis
    • InvivoGen
    • Associated British Foods
    • GlaxoSmithKline plc.
    • Croda International Plc
    • Dynavax Technologies Corporation

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Moderate intensity of rivalry
    • 3.3.2. Moderate bargaining power of buyers
    • 3.3.3. Moderate bargaining power of suppliers
    • 3.3.4. High threat of new entrants
    • 3.3.5. Moderate threat of substitutes
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Increase in prevalence of infectious diseases
      • 3.4.1.2. Growing funding for vaccines and infectious diseases
      • 3.4.1.3. Expansion of vaccination programs
    • 3.4.2. Restraints
      • 3.4.2.1. High initial and R&D cost
    • 3.4.3. Opportunities
      • 3.4.3.1. Growth opportunities in emerging markets
      • 3.4.3.2. Advancements in vaccine adjuvant research

CHAPTER 4: VACCINE ADJUVANTS MARKET, BY TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Immunostimulants
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
    • 4.2.4. Immunostimulants Vaccine Adjuvants Market by Type
  • 4.3. Vehicles and Mucosal Adjuvants
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country

CHAPTER 5: VACCINE ADJUVANTS MARKET, BY DISEASE

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Infectious Diseases
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
    • 5.2.4. Infectious Diseases Vaccine Adjuvants Market by Type
  • 5.3. Others
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country

CHAPTER 6: VACCINE ADJUVANTS MARKET, BY APPLICATION

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Research
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Commercial
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country

CHAPTER 7: VACCINE ADJUVANTS MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key market trends, growth factors and opportunities
    • 7.2.2. Market size and forecast, by Type
    • 7.2.3. Market size and forecast, by Disease
    • 7.2.4. Market size and forecast, by Application
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Market size and forecast, by Type
      • 7.2.5.1.2. Market size and forecast, by Disease
      • 7.2.5.1.3. Market size and forecast, by Application
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Market size and forecast, by Type
      • 7.2.5.2.2. Market size and forecast, by Disease
      • 7.2.5.2.3. Market size and forecast, by Application
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Market size and forecast, by Type
      • 7.2.5.3.2. Market size and forecast, by Disease
      • 7.2.5.3.3. Market size and forecast, by Application
  • 7.3. Europe
    • 7.3.1. Key market trends, growth factors and opportunities
    • 7.3.2. Market size and forecast, by Type
    • 7.3.3. Market size and forecast, by Disease
    • 7.3.4. Market size and forecast, by Application
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Market size and forecast, by Type
      • 7.3.5.1.2. Market size and forecast, by Disease
      • 7.3.5.1.3. Market size and forecast, by Application
      • 7.3.5.2. France
      • 7.3.5.2.1. Market size and forecast, by Type
      • 7.3.5.2.2. Market size and forecast, by Disease
      • 7.3.5.2.3. Market size and forecast, by Application
      • 7.3.5.3. UK
      • 7.3.5.3.1. Market size and forecast, by Type
      • 7.3.5.3.2. Market size and forecast, by Disease
      • 7.3.5.3.3. Market size and forecast, by Application
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Market size and forecast, by Type
      • 7.3.5.4.2. Market size and forecast, by Disease
      • 7.3.5.4.3. Market size and forecast, by Application
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Market size and forecast, by Type
      • 7.3.5.5.2. Market size and forecast, by Disease
      • 7.3.5.5.3. Market size and forecast, by Application
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Market size and forecast, by Type
      • 7.3.5.6.2. Market size and forecast, by Disease
      • 7.3.5.6.3. Market size and forecast, by Application
  • 7.4. Asia-Pacific
    • 7.4.1. Key market trends, growth factors and opportunities
    • 7.4.2. Market size and forecast, by Type
    • 7.4.3. Market size and forecast, by Disease
    • 7.4.4. Market size and forecast, by Application
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. Japan
      • 7.4.5.1.1. Market size and forecast, by Type
      • 7.4.5.1.2. Market size and forecast, by Disease
      • 7.4.5.1.3. Market size and forecast, by Application
      • 7.4.5.2. China
      • 7.4.5.2.1. Market size and forecast, by Type
      • 7.4.5.2.2. Market size and forecast, by Disease
      • 7.4.5.2.3. Market size and forecast, by Application
      • 7.4.5.3. India
      • 7.4.5.3.1. Market size and forecast, by Type
      • 7.4.5.3.2. Market size and forecast, by Disease
      • 7.4.5.3.3. Market size and forecast, by Application
      • 7.4.5.4. Australia
      • 7.4.5.4.1. Market size and forecast, by Type
      • 7.4.5.4.2. Market size and forecast, by Disease
      • 7.4.5.4.3. Market size and forecast, by Application
      • 7.4.5.5. South Korea
      • 7.4.5.5.1. Market size and forecast, by Type
      • 7.4.5.5.2. Market size and forecast, by Disease
      • 7.4.5.5.3. Market size and forecast, by Application
      • 7.4.5.6. Rest of Asia-Pacific
      • 7.4.5.6.1. Market size and forecast, by Type
      • 7.4.5.6.2. Market size and forecast, by Disease
      • 7.4.5.6.3. Market size and forecast, by Application
  • 7.5. Latin America
    • 7.5.1. Key market trends, growth factors and opportunities
    • 7.5.2. Market size and forecast, by Type
    • 7.5.3. Market size and forecast, by Disease
    • 7.5.4. Market size and forecast, by Application
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Brazil
      • 7.5.5.1.1. Market size and forecast, by Type
      • 7.5.5.1.2. Market size and forecast, by Disease
      • 7.5.5.1.3. Market size and forecast, by Application
      • 7.5.5.2. Colombia
      • 7.5.5.2.1. Market size and forecast, by Type
      • 7.5.5.2.2. Market size and forecast, by Disease
      • 7.5.5.2.3. Market size and forecast, by Application
      • 7.5.5.3. Argentina
      • 7.5.5.3.1. Market size and forecast, by Type
      • 7.5.5.3.2. Market size and forecast, by Disease
      • 7.5.5.3.3. Market size and forecast, by Application
      • 7.5.5.4. Rest of Latin America
      • 7.5.5.4.1. Market size and forecast, by Type
      • 7.5.5.4.2. Market size and forecast, by Disease
      • 7.5.5.4.3. Market size and forecast, by Application
  • 7.6. Middle East and Africa
    • 7.6.1. Key market trends, growth factors and opportunities
    • 7.6.2. Market size and forecast, by Type
    • 7.6.3. Market size and forecast, by Disease
    • 7.6.4. Market size and forecast, by Application
    • 7.6.5. Market size and forecast, by country
      • 7.6.5.1. Gcc
      • 7.6.5.1.1. Market size and forecast, by Type
      • 7.6.5.1.2. Market size and forecast, by Disease
      • 7.6.5.1.3. Market size and forecast, by Application
      • 7.6.5.2. South Africa
      • 7.6.5.2.1. Market size and forecast, by Type
      • 7.6.5.2.2. Market size and forecast, by Disease
      • 7.6.5.2.3. Market size and forecast, by Application
      • 7.6.5.3. North Africa
      • 7.6.5.3.1. Market size and forecast, by Type
      • 7.6.5.3.2. Market size and forecast, by Disease
      • 7.6.5.3.3. Market size and forecast, by Application
      • 7.6.5.4. Rest of Middle East And Africa
      • 7.6.5.4.1. Market size and forecast, by Type
      • 7.6.5.4.2. Market size and forecast, by Disease
      • 7.6.5.4.3. Market size and forecast, by Application

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product mapping of top 10 player
  • 8.4. Competitive dashboard
  • 8.5. Competitive heatmap
  • 8.6. Top player positioning, 2023

CHAPTER 9: COMPANY PROFILES

  • 9.1. Dynavax Technologies Corporation
    • 9.1.1. Company overview
    • 9.1.2. Key executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Business performance
    • 9.1.7. Key strategic moves and developments
  • 9.2. Novovax Inc.
    • 9.2.1. Company overview
    • 9.2.2. Key executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
    • 9.2.6. Business performance
    • 9.2.7. Key strategic moves and developments
  • 9.3. Agenus Inc.
    • 9.3.1. Company overview
    • 9.3.2. Key executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
    • 9.3.6. Business performance
    • 9.3.7. Key strategic moves and developments
  • 9.4. Adjuvatis
    • 9.4.1. Company overview
    • 9.4.2. Key executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
  • 9.5. Aurorium
    • 9.5.1. Company overview
    • 9.5.2. Key executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
    • 9.5.6. Key strategic moves and developments
  • 9.6. InvivoGen
    • 9.6.1. Company overview
    • 9.6.2. Key executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
  • 9.7. Croda International Plc
    • 9.7.1. Company overview
    • 9.7.2. Key executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
    • 9.7.6. Business performance
    • 9.7.7. Key strategic moves and developments
  • 9.8. Air Liquide Group
    • 9.8.1. Company overview
    • 9.8.2. Key executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
    • 9.8.6. Business performance
  • 9.9. Associated British Foods
    • 9.9.1. Company overview
    • 9.9.2. Key executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
    • 9.9.6. Business performance
    • 9.9.7. Key strategic moves and developments
  • 9.10. GlaxoSmithKline plc.
    • 9.10.1. Company overview
    • 9.10.2. Key executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio
    • 9.10.6. Business performance
    • 9.10.7. Key strategic moves and developments